Neurocrine Biosciences, Inc. announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia (TD) achieved a therapeutic dose with INGREZZA capsules upon initiation of treatment. This retrospective cohort study was presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting.
The study, utilizing IQVIA's U.S. databases, included 3,527 patients on INGREZZA, 2,166 on deutetrabenazine twice daily (BID), and 326 on deutetrabenazine extended release (XR). Results showed that 100% of INGREZZA patients achieved a therapeutic dose from day one, compared to 50% of deutetrabenazine BID patients and 49% of deutetrabenazine XR patients reaching a therapeutic dose within six months.
This finding provides critical insights into the real-world use of VMAT2 inhibitors, demonstrating that INGREZZA provides a therapeutic dose from day one without the need for titration. This potentially reduces clinician and patient burden associated with sub-therapeutic dosing, offering a clear advantage over competitors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.